Hyrimoz (Adalimumab)

Adalimumab is a monoclonal antibody that specifically binds to tumor necrosis factor‑alpha (TNF‑α), a key cytokine in inflammation. By neutralising TNF‑α, it blocks the cascade of inflammatory signals, decreasing immune cell activation and reducing tissue damage in affected organs.

The dosage of Hyrimoz is individualized by the prescribing healthcare professional based on the specific indication, patient weight, and clinical response. Only a qualified prescriber can determine the appropriate dosing schedule and administration frequency.

Hyrimoz is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but insufficient human data. It should only be used during pregnancy if the potential benefit justifies the potential risk. Breastfeeding mothers should discuss risks with their physician, as the drug may be present in breast milk.

To place an order, submit an enquiry on the Hyrimoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Hyrimoz (adalimumab) is a fully human monoclonal antibody, whereas alternatives like infliximab are chimeric antibodies and etanercept is a fusion protein. Adalimumab offers the convenience of subcutaneous self‑administration without the need for infusion, and its safety profile is comparable, though individual patient response may vary.

Hyrimoz should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If temporary temperature excursions occur, consult the product label before use.

Hyrimoz is supplied as a solution for injection and is administered subcutaneously, typically in the thigh, abdomen, or upper arm. Patients are trained to use a pre‑filled syringe or autoinjector, and the injection site should be rotated to minimise local reactions.

The most serious risks include severe infections such as tuberculosis, opportunistic fungal or bacterial infections, reactivation of hepatitis B, malignancies (including lymphoma), and demyelinating neurological disorders. Patients should be monitored regularly for signs of infection or unusual symptoms.

Hyrimoz is contraindicated in patients with known hypersensitivity to adalimumab or any component of the formulation. It should also be avoided in individuals with active, severe infections, uncontrolled heart failure, or those receiving live vaccines. A thorough medical assessment is required before initiation.